14.595
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aduro Biotech Inc | ADRO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 14.595 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 14.595 | 14.595 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 14.60 | 17.00 | 2.40 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 14.595 | USD |
Aduro Biotech Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 236.61M | 16.21M | 13.20M | $ 17.26M | $ - | -5.10 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -66.69k | 2.20% |
Aduro Biotech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADRO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 2.76 | 15.7283 | 2.20 | 3.13 | 527,516 | 11.84 | 428.8% |
| 1 Year | 1.46 | 15.7283 | 1.34 | 2.80 | 742,738 | 13.14 | 899.66% |
| 3 Years | 6.80 | 15.7283 | 0.9011 | 3.43 | 624,397 | 7.80 | 114.63% |
| 5 Years | 18.34 | 18.875 | 0.9011 | 5.98 | 531,562 | -3.75 | -20.42% |
Aduro Biotech Description
| Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy. |
